Related Experiment Video
Updated: Jul 6, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Targeted therapy for multiple gene mutations in multiple metastases of advanced gastric cancer: a case report
Xin Zhang1, Xinran Zhang1, Dandan Geng2
1Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Abstract:
In China, gastric cancer is the second most common cause of cancer-related death, after lung cancer. At present, the morbidity and mortality rates of gastric cancer are increasing, and targeted therapy for gastric cancer has become a research hotspot. Herein, we report a patient with multiple metastases from advanced gastric cancer. After identifying MET gene amplification, initial treatment induced regression of the tumor. However, in later stages, due to the overexpression or mutation of HER-2, KRAS, TP53, and other genes, the targeted drug therapy became ineffective, and the disease progressed rapidly, leading to the death of the patient.
Insights
Targeted therapy for advanced gastric cancer initially worked after identifying MET gene amplification. However, resistance developed due to HER-2, KRAS, and TP53 mutations, leading to treatment failure and rapid disease progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastric cancer is a leading cause of cancer death in China, with rising incidence and mortality.
- Targeted therapy represents a critical research area for advanced gastric cancer treatment.
Observation:
- A patient with advanced gastric cancer and multiple metastases was treated.
- Initial treatment targeting MET gene amplification led to tumor regression.
Findings:
- The patient developed resistance to targeted therapy.
- Overexpression or mutation of HER-2, KRAS, and TP53 genes contributed to treatment ineffectiveness.
- Rapid disease progression and patient death occurred despite initial response.
Implications:
- This case highlights the challenge of acquired resistance in advanced gastric cancer targeted therapy.
- Understanding genetic alterations like HER-2, KRAS, and TP53 mutations is crucial for overcoming treatment resistance.
- Further research into novel therapeutic strategies is needed to improve outcomes for gastric cancer patients.
More Related Videos
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...